Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cocaine esterase - Tonix Pharmaceuticals Holding Corp

Drug Profile

Cocaine esterase - Tonix Pharmaceuticals Holding Corp

Alternative Names: Cocaine esterase; RBP 8000; T172R/G173G cocaine esterase; T172R/G173Q double-mutant cocaine esterase; TNX 1300

Latest Information Update: 08 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University; University of Kentucky; University of Michigan
  • Developer Indivior
  • Class Antidotes; Carboxylic ester hydrolases; Drug withdrawal therapies
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cocaine-related disorders

Most Recent Events

  • 01 Apr 2024 Tonix Pharmaceuticals plans a phase II trial for Cocaine-related disorders in the US in the second quarter of 2024
  • 13 Mar 2023 Tonix Pharmaceuticals has patent protection for Cocaine esterase in Canada, New Zealand, Europe – (Germany, Spain, France, United Kingdom, and Italy), South Africa, Mexico and Israel
  • 16 Jun 2022 Tonix Pharmaceuticals withdraws a phase II trial prior to enrolment in Cocaine-related disorders in USA (IV), due to not able to recruit qualified participants (NCT04996056)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top